Guía de laboratorio · Compuestos mitocondriales
¿Qué es el SS-31? Resumen de la investigación sobre péptidos dirigidos a las mitocondrias
What is SS-31? It is a synthetic tetrapeptide, D-Arg-Dmt-Lys-Phe-NH2, also called elamipretide, that concentrates in the inner mitochondrial membrane and binds cardiolipin. This guide covers its structure, the cardiolipin mechanism reported in the original studies, and its unusual regulatory position among research peptides.
Puntos clave
- SS-31 is a four-residue peptide, D-Arg-Dmt-Lys-Phe-NH2, with the formula C32H49N9O5 and a molecular weight of 639.8 g/mol.
- It carries a 3+ net charge and an alternating aromatic-cationic motif, and it accumulates in the inner mitochondrial membrane.
- Birk et al. (2013) reported high-affinity binding to cardiolipin and inhibition of cytochrome c peroxidase activity in ischaemia models.
- In September 2025 the FDA granted accelerated approval to an elamipretide medicine for Barth syndrome; research-grade SS-31 is a different, unapproved reagent.
¿Qué es el SS-31?
So, what is SS-31? SS-31 is a synthetic tetrapeptide of the Szeto-Schiller family, designed around an alternating cationic-aromatic motif. It is also known as elamipretide, MTP-131 or Bendavia. A 2014 review describes it as having a 3+ net charge and as selectively binding cardiolipin (PMC).
Unusually for a research peptide, an elamipretide medicine now has a regulatory approval in one jurisdiction. That is covered below, and it does not apply to research-grade SS-31.
Solo para uso en investigación. Esta descripción general resume los estudios publicados de investigación en laboratorio y con animales. Baltic Peptides suministra este compuesto para investigación in vitro y preclínica a investigadores cualificados; no es un medicamento y no está destinado al uso humano ni veterinario.
Estructura química y especificaciones
| Propiedad | Valor |
|---|---|
| Secuencia | D-Arg-Dmt-Lys-Phe-NH2 (Dmt = 2′,6′-dimethyltyrosine) |
| Longitud | 4 residues, C-terminal amide |
| Fórmula molecular | C32H49N9O5 |
| Peso molecular | 639.8 g/mol (average); 639.386 Da monoisotopic, calculated |
| CID de PubChem | 11764719 |
| Net charge | 3+ at physiological pH |
The formula, mass and sequence match the PubChem record for elamipretide. Two non-standard features matter analytically: the D-arginine at position 1 and the dimethyltyrosine at position 2, which are not found in natural proteins. A mass is the same for an L-isomer, so identity depends on chromatography as well as mass.
Historia de los descubrimientos y la investigación
Hazel Szeto and Peter Schiller developed the SS peptides, and Szeto has described how the compounds were discovered serendipitously, noting that it was “highly unexpected” for a 640 Da, highly polar, triply charged peptide to cross membranes and concentrate in mitochondria (Szeto, 2014).
The cardiolipin mechanism was identified later. Birk et al. (2013, J Am Soc Nephrol) used a polarity-sensitive fluorescent analogue to show that SS-31 binds cardiolipin with high affinity.
Mechanism: cardiolipin binding
Targeting the inner membrane
Cardiolipin is an anionic phospholipid confined to the inner mitochondrial membrane and required for cristae formation. The positive charges of SS-31 interact electrostatically with the phosphate head groups, aligning the aromatic residues in the hydrophobic acyl-chain region, at a 1:1 molar ratio ({A(“https://pmc.ncbi.nlm.nih.gov/articles/PMC3976620/”,”PMC”)}).
Reported consequences
In the 2013 study, the SS-31/cardiolipin complex inhibited cytochrome c peroxidase activity, which catalyses cardiolipin peroxidation and mitochondrial damage during ischaemia, by protecting the heme iron. The authors concluded that SS-31 protects mitochondrial cristae in ischaemic models (Birk et al., 2013). Later reviews describe stabilised respiratory supercomplexes and reduced reactive oxygen species, which remain interpretations of model data.
Principales áreas de investigación
- Cardiolipin and cristae biology: binding, supercomplex stability and cytochrome c peroxidase activity.
- Bioenergetics: ATP production and ROS output under ischaemia-reperfusion and oxidative stress.
- Cardiac and skeletal muscle models: preclinical work on ischaemia-reperfusion and muscle function.
- Ageing and mitochondrial decline: restoration of mitochondrial morphology in aged tissues in rodent studies.
Lo que realmente muestran los estudios publicados
SS-31 has a much larger human record than most compounds in this series. On September 19, 2025, the FDA granted accelerated approval to Forzinity (elamipretide) to improve muscle strength in adult and paediatric patients with Barth syndrome weighing at least 30 kg (FDA approval letter). A confirmatory trial is a condition of that accelerated approval (PubMed).
| Tipo de prueba | Lo que se informa |
|---|---|
| Datos químicos | La secuencia, la fórmula y la masa pueden verificarse en la base de datos. |
| Binding studies | High-affinity cardiolipin binding and 1:1 stoichiometry in model membranes. |
| Estudios con animales | Protective bioenergetic effects in ischaemia, cardiac and ageing models. |
| Normativo | One accelerated approval, for a pharmaceutical-grade product, in one indication and one jurisdiction. |
That approval is a regulatory fact about a specific medicine. It does not make research-grade SS-31 a medicine, and it does not establish effects in any other setting.
Limitaciones científicas y cuestiones pendientes
- The approval covers one indication, and accelerated approval requires confirmatory evidence of benefit.
- Trials in other indications have given mixed results and have not led to approval.
- Cardiolipin binding is shown in model systems; downstream effects in vivo remain interpretations.
- Approval of a pharmaceutical product does not apply to research-grade material.
- It is not authorised as a medicine in the EU.
Consideraciones analíticas y de laboratorio
SS-31 is small and highly water-soluble, with no methionine or cysteine, so it is simpler to handle than larger peptides. Its D-Arg and Dmt residues mean that mass spectrometry should show 639.8 Da and chromatography should separate any L-isomer impurity, which has the same mass.
See how to store peptides and the guide to reading a peptide COA. Batch reports are on the COA page, and formats are on the SS-31 product page.
Fuentes y lecturas recomendadas
- Birk A.V. et al. (2013). The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. J Am Soc Nephrol 24(8):1250-1261. PubMed
- Szeto H.H. (2014). First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. PMC full text
- FDA (2025). Forzinity (elamipretide) accelerated approval letter, NDA 215244. FDA · Elamipretide: First Approval (PubMed)
- PubChem compound record for elamipretide (CID 11764719). PubChem
Todos los productos de Baltic Peptides se suministran exclusivamente para uso en investigación de laboratorio. No son medicamentos, complementos alimenticios ni alimentos, y no están destinados al consumo humano ni animal. Este artículo resume los estudios publicados con fines exclusivamente educativos y no describe ningún uso en personas.
Preguntas frecuentes
Preguntas frecuentes
¿Qué es el SS-31?
What is the difference between SS-31 and elamipretide?
What is the sequence and molecular weight of SS-31?
¿Cómo llega el SS-31 a las mitocondrias?
What is cardiolipin?
Is SS-31 an approved medicine?
How is SS-31 different from MOTS-c?
Sigue leyendo
Lecturas relacionadas
SS-31
Current batches, formats and the COA for SS-31.
¿Qué es el NAD+?
The coenzyme at the centre of mitochondrial energy research.
¿Qué es MOTS-c?
Un péptido de origen mitocondrial relacionado con la señalización de la AMPK.
Research-grade SS-31, tested before it ships
Resultados independientes de análisis por espectrometría de masas ( HPLC ) para cada lote expedido desde la UE.
